Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty

Deborah W. Sundlof; Pairoj Rerkpattanapitat; Nattawut Wongpraparut; Padmavathi Pathi; Morris N. Kotler; Larry E. Jacobs; Gary S. Ledley; Shahriar Yazdanfar

doi:10.1016/S0002-9149(99)00151-4

Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty

Deborah W. Sundlof
, Pairoj Rerkpattanapitat
, Nattawut Wongpraparut
, Padmavathi Pathi
, Morris N. Kotler
, Larry E. Jacobs
, Gary S. Ledley
, Shahriar Yazdanfar

Albert Einstein Medical Center

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

The use of abcimixab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.

Original language	English
Pages (from-to)	1569-1570
Number of pages	2
Journal	American Journal of Cardiology
Volume	83
Issue number	11
DOIs	https://doi.org/10.1016/S0002-9149(99)00151-4
Publication status	Published - 1 Jun 1999
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0002-9149(99)00151-4

Cite this

Sundlof, D. W., Rerkpattanapitat, P., Wongpraparut, N., Pathi, P., Kotler, M. N., Jacobs, L. E., Ledley, G. S., & Yazdanfar, S. (1999). Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 83(11), 1569-1570. https://doi.org/10.1016/S0002-9149(99)00151-4

@article{e082a4ef7ab94d73863e15b8273b6972,

title = "Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty",

abstract = "The use of abcimixab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.",

author = "Sundlof, \{Deborah W.\} and Pairoj Rerkpattanapitat and Nattawut Wongpraparut and Padmavathi Pathi and Kotler, \{Morris N.\} and Jacobs, \{Larry E.\} and Ledley, \{Gary S.\} and Shahriar Yazdanfar",

year = "1999",

month = jun,

day = "1",

doi = "10.1016/S0002-9149(99)00151-4",

language = "English",

volume = "83",

pages = "1569--1570",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "11",

}

Sundlof, DW, Rerkpattanapitat, P, Wongpraparut, N, Pathi, P, Kotler, MN, Jacobs, LE, Ledley, GS & Yazdanfar, S 1999, 'Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty', American Journal of Cardiology, vol. 83, no. 11, pp. 1569-1570. https://doi.org/10.1016/S0002-9149(99)00151-4

Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. / Sundlof, Deborah W.; Rerkpattanapitat, Pairoj; Wongpraparut, Nattawut et al.
In: American Journal of Cardiology, Vol. 83, No. 11, 01.06.1999, p. 1569-1570.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty

AU - Sundlof, Deborah W.

AU - Rerkpattanapitat, Pairoj

AU - Wongpraparut, Nattawut

AU - Pathi, Padmavathi

AU - Kotler, Morris N.

AU - Jacobs, Larry E.

AU - Ledley, Gary S.

AU - Yazdanfar, Shahriar

PY - 1999/6/1

Y1 - 1999/6/1

N2 - The use of abcimixab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.

AB - The use of abcimixab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.

UR - https://www.scopus.com/pages/publications/0033153133

U2 - 10.1016/S0002-9149(99)00151-4

DO - 10.1016/S0002-9149(99)00151-4

M3 - Article

C2 - 10363875

AN - SCOPUS:0033153133

SN - 0002-9149

VL - 83

SP - 1569

EP - 1570

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 11

ER -

Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this